INTRODUCTION

Despite recent advances in the treatment of non-Hodgkin’s lymphoma (NHL), some patients with advanced stage diffuse large B-cell lymphoma (DLBCL) are not cured by conventional chemotherapy alone, resulting in...

Background/Aims: Several studies have demonstrated the effect of autologous hematopoietic stem cell transplantation (auto-HSCT) as a salvage treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL). However, the role of auto-HSCT as a frontline treatment has not been fully investigated in the rituximab era. We validated the age-adjusted International Prognostic Index (aaIPI) score for high-risk DLBCL patients and identified a possible role for frontline auto-HSCT.

Methods: We recommended frontline auto-HSCT for high-risk DLBCL patients who satisfied the criteria of both a higher Ann-Arbor stage (III to IV) and an elevated lactate dehydrogenase (LDH) level at diagnosis with an aaIPI score $\geq 2$. From 2006 to 2011, among the 150 DLBCL patients aged $\leq 60$ years who were treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), 23 high-risk patients with a complete response (CR) were treated with auto-HSCT. For comparison, we selected 35 well-matched high-risk patients with CR who completed R-CHOP treatment alone. In addition, there were 81 low-risk patients and 11 refractory patients.

Results: DLBCL patients with an aaIPI score $\geq 2$ showed inferior overall survival (OS; $p = 0.040$) and progression-free survival (PFS; $p = 0.007$) compared to the aaIPI score 0 to 1. Between the two treatment arms among the high-risk DLBCL patients, the clinical parameters were not different. The high-risk group treated with frontline auto-HSCT showed similar OS ($p = 0.392$) and PFS ($p = 0.670$) to those in the low-risk group. Thus, frontline auto-HSCT showed superior PFS ($p = 0.004$), but only a trend towards favorable OS ($p = 0.091$) compared to R-CHOP alone.

Conclusions: We identified the possible role of frontline auto-HSCT for high-risk DLBCL with a higher stage (III to IV) and elevated LDH level.

Keywords: Lymphoma; Lymphoma, large B-cell, diffuse; Autologous hematopoietic cell transplantation
poor survival outcomes. The role of high-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) has been proven in chemosensitive-relapsed DLBCL [1,2]. However, as a frontline treatment, the role of auto-HSCT is not well recognized, although several randomized studies have evaluated its efficacy during the first remission in high-risk aggressive NHL, including DLBCL.

Several studies addressed the issue before the rituximab era. The French Groupe d’Étude des Lymphomes de l’Adulte (GELA) study [3] and an Italian study [4] showed the benefit of auto-HSCT during the first remission in a subset of patients with a high-intermediate or high risk according to the age-adjusted International Prognostic Index (aaIPI) score. Milpied et al. [5] showed a favorable outcome of auto-HSCT compared to chemotherapy alone in the high-intermediate risk group according to aaIPI, but there were no differences in the event-free survival (EFS) and overall survival (OS) for patients with low or low-intermediate risk. These studies support the role of frontline auto-HSCT in patients with high-risk aggressive DLBCL; however, the benefit was mostly shown in good responders to induction chemotherapy [6]. Conversely, the outcomes of frontline auto-HSCT were similar or inferior to conventional chemotherapy in other reports [7,8]. While none of these trials included rituximab, several randomized phase III trials recently evaluated the role of auto-HSCT after the advent of rituximab-containing immunochemotherapy [9-12].

Given the improved outcome with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in both younger [13] and older patients with DLBCL [14], it is possible that the benefit of auto-HSCT during the first complete remission may be abrogated by the addition of rituximab, as observed when rituximab was added to dose-intensified chemotherapy (CHOP-14 or CHOEP-14) [15]. Here, we validated the aaIPI score for high-risk DLBCL patients who might be expected to achieve favorable survival outcomes when treated with frontline auto-HSCT. In addition, we compared the clinical outcomes of auto-HSCT and R-CHOP alone among the high-risk DLBCL patients who achieved complete response (CR) after six cycles of R-CHOP.

METHODS

Patients and definitions for response evaluation

Between June 2006 and December 2011, 186 patients with newly diagnosed DLBCL at the Catholic Blood and Marrow Transplantation Center in South Korea were included in the study. All of the analyses were performed according to the Institutional Review Board guidelines of the Catholic Medical Center with respect to the Declaration of Helsinki. The diagnosis of DLBCL was based on morphological studies with immunohistochemical analysis. Among the 186 DLBCL patients, we first selected 150 patients aged ≤ 60 years, because all of the patients who underwent frontline auto-HSCT were aged ≤ 60 years. We identified 23 patients who underwent planned frontline auto-HSCT after six cycles of R-CHOP due to a high-risk status at initial presentation (high-risk, auto-HSCT group). The remaining patients were treated with six cycles of R-CHOP and completed treatment with chemotherapy alone or underwent salvage chemotherapy. After three cycles of R-CHOP, the response was evaluated by both computed tomography (CT) and fluorine 18-fluorodeoxyglucose positron emission tomography (FDG-PET). If the patients achieved a CR or a partial response (PR), we applied an additional three cycles of R-CHOP (for a total of six cycles) and completed treatment if the patients achieved CR. When the disease progressed during treatment, or if the patients failed to achieve at least PR (chemorefractory status), we changed the regimen to salvage chemotherapy. To determine the treatment outcome of frontline auto-HSCT compared to R-CHOP alone in high-risk DLBCL patients with CR, we selected 35 well-matched patients with a similar risk status and performance status (PS), and all of the patients were without significant comorbidities. All of the 35 patients were in CR after six cycles of R-CHOP and completed treatment (high-risk, R-CHOP alone group) (Fig. 1).

The definition of CR required regression of the entire palpable mass and regression to a normal size on CT with negative FDG-PET. FDG-PET was evaluated according to the criteria of the standardized uptake value [16]. CT and FDG-PET were performed after every three cycles of R-CHOP and 1 month before HSCT. If bone marrow (BM) was initially involved, a BM biopsy was performed after six cycles of R-CHOP. PR required...
a reduction of at least 50% in the sum of the products of the dimensions on CT with positive FDG-PET without a newly developed lesion. Disease progression was defined as an increase in the lesion size of more than 25% compared to the sum of the sizes of the pretreatment lesions, or the appearance of new lesions. Relapse was defined as new disease in CR patients or progressive disease in PR patients.

Patients treated with frontline auto-HSCT
We calculated the IPI [17] and aaIPI [18] scores in all patients at diagnosis, and started R-CHOP chemotherapy. In calculating the IPI score, we found that an initial poor PS might improve during chemotherapy, and the extranodal status was highly correlated with Ann Arbor stage. For auto-HSCT candidates, we selected high-risk DLBCL patients aged 60 years or younger who satisfied the criteria of both an elevated lactate dehydrogenase (LDH) level (≥ 450 U/L) and a higher Ann Arbor stage (III to IV) at initial presentation that conclusively resulted in aaIPI ≥ 2 (high-intermediate to high risk). PS and extranodal status were not used to select high-risk patients. After three cycles of R-CHOP, all of the high-risk patients (aged ≤ 60 years) in CR or PR were recommended for auto-HSCT after explaining the relapse risk and necessity for high-dose chemotherapy. Conclusively, frontline auto-HSCT was performed strictly according to the patient's final decision, and the comparative R-CHOP alone group consisted of patients who satisfied the criteria of the same high-risk DLBCL category with similar PS and comorbidities.

Treatment protocols
To initiate R-CHOP chemotherapy, rituximab was infused at 375 mg/m² on day 1, and then every 3 weeks. Chemotherapies included cyclophosphamide (750 mg/m², administered intravenously on day 1), doxorubicin (50 mg/m², administered intravenously on day 1), vincristine (1.4 mg/m², but not more than 2.0 mg in total, administered intravenously on day 1), and prednisolone (100 mg/m², orally administered on days 1 to 5) every 3 weeks [19]. Autologous stem cell mobilization was performed after three cycles of R-CHOP as well as response evaluation of patients in whom auto-HSCT was planned. We started with granulocyte-colony stimulating factor (filgrastim, 10 µg/kg) at 48 hours after the sixth cycle of R-CHOP, and when the leukocyte count and peripheral CD34 count were elevated, we performed apheresis. For auto-HSCT, we used a BuMelITT protocol that consisted of intravenous busulfan, melphalan, and thiotepa with a 20% dose reduction compared to that in previous reports [20-22]. Our dose-reduction was based on our own experiences and previous reports (including one Korean report) that addressed the excessive toxicity of the BuMelITT protocol [23,24]. Busulfan was administered at a dose of 2.4 mg/kg/day for three consecutive days (D-8, D-7, and D-6; total 7.2 mg/kg); melphalan was administered at a dose of 40 mg/m² per day for 2 days (D-5 and D-4; total, 80 mg/m²); and thiotepa was administered at a dose of 200 mg/m² per day for 2 consecutive days (D-3 and D-2; total, 400 mg/m²). Stem cells were infused 48 hours after the final dose of thiotepa.

Statistical analysis
The purpose of this study was to assess the clinical outcomes in high-risk DLBCL patients according to the treatment strategy: frontline auto-HSCT versus R-CHOP alone. All of the categorical variables were compared by chi-square analysis and Fisher exact test, and continuous variables were assessed by Student t test.
and Wilcoxon rank-sum test. OS measured the proportion of people who were alive at a specified time from diagnosis, and progression-free survival (PFS) measured the proportion of progression or death from any cause from the first day of R-CHOP. EFS was measured from diagnosis to any treatment failure, including disease progression, death, discontinuation of treatment for any reason, or initiation of new treatment without documented progression. Survival outcomes were estimated using the Kaplan-Meier survival method, and log-rank analysis was used to evaluate differences between survival distributions under various clinical conditions. A Cox proportional regression model was used to calculate the survival hazard ratio (HR). All of the statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and R software version 2.15.1 (The R Foundation for Statistical Computing, 2012; http://www.r-project.org/). Statistical significance was set at a $p$ value less than 0.05.

RESULTS

Patient baseline characteristics

Fig. 1 shows the Consolidated Standards of Reporting Trials (CONSORT) diagram for DLBCL patients treated at the Catholic BMT Center. Among the 150 DLBCL patients aged $\leq 60$ years who were treated with six cycles of R-CHOP, 124 (82.6%) achieved CR and 21 (14.0%) achieved PR. Five patients (3.4%) were refractory to R-CHOP chemotherapy. Among the 21 patients with PR, 15 low-risk patients completed therapy with R-CHOP alone. The remaining six high-risk patients with PR and five refractory patients were treated with immediate salvage chemotherapy. Among the 124 patients with CR after R-CHOP, 66 were low-risk patients (53.3%) who completed therapy with R-CHOP alone, and the remaining 58 were high-risk patients (46.7%) with aaIPI $\geq 2$ satisfying the criteria of both an elevated LDH level and a higher Ann Arbor stage (III to IV). Fifty-eight high-risk patients were divided into two groups according to the treatment: a frontline auto-HSCT group ($n = 23$) and an R-CHOP alone group ($n = 35$). Between the two groups, the distributions of age, gender, IPI score, aaIPI score, and Ann Arbor stage at initial presentation were not significantly different. In addition, the diagnostic LDH level, distribution of Eastern Cooperative Oncology Group status, and extranodal involvement status (including BM) were not different. Overall, the entire cohort was divided into four groups according to the risk stratification and treatment strategies: a low-risk group that completed treatment with R-CHOP alone ($n = 81$), a high-risk group treated with frontline auto-HSCT ($n = 23$), a high-risk group treated with R-CHOP alone ($n = 35$), and a non-CR group treated with immediate salvage chemotherapy ($n = 11$). The baseline characteristics are displayed in Table 1.

Survival outcomes according to risk stratification and treatments

DLBCL patients with an aaIPI score $\geq 2$ showed significantly inferior OS (HR, 2.191; 95% confidence interval [CI], 1.119 to 4.291; $p = 0.040$) and PFS (HR, 2.192; 95% CI, 1.249 to 3.848; $p = 0.007$) compared to an aaIPI score 0 to 1 (Fig. 2). Next, we compared the clinical outcomes of the four patient groups divided according to risk and treatment strategies. The high-risk group treated with auto-HSCT showed similar OS (HR, 1.602; 95% CI, 0.544 to 4.715; $p = 0.392$), PFS (HR, 1.234; 95% CI, 0.469 to 3.248; $p = 0.670$), and EFS (HR, 1.030; 95% CI, 0.389 to 2.725; $p = 0.952$) to that of the low-risk group. In addition, both the high-risk group treated with auto-HSCT and the low-risk group showed superior PFS (HR, 0.338; $p = 0.022$) and HR 0.274 ($p < 0.001$), respectively, and EFS (HR, 0.297; $p = 0.013$) and HR 0.288 ($p < 0.001$), respectively, compared to the high-risk group treated with R-CHOP alone. However, only the low-risk group showed superior OS (HR, 0.338; 95% CI, 0.148 to 0.772; $p = 0.110$), whereas the high-risk group treated with auto-HSCT did not show significantly superior OS (HR, 0.542; 95% CI, 0.192 to 1.528; $p = 0.102$) compared to the high-risk group treated with R-CHOP alone (Fig. 3). There was no therapy-related mortality after auto-HSCT.

Frontline auto-HSCT versus R-CHOP alone for high-risk DLBCL

Conclusively, among the high-risk DLBCL patients, Kaplan-Meier analysis estimated that frontline auto-HSCT showed significantly superior PFS ($p = 0.004$), but showed only a trend towards favorable OS ($p = 0.091$) compared to R-CHOP alone (Fig. 4). With a median follow-up duration of 30.5 months (range, 10.1 to 77.1),
frontline auto-HSCT showed 3-year OS and PFS rates of 75% and 66%, respectively, whereas the R-CHOP alone group showed 3-year OS and PFS rates of 49% and 39%, respectively. In addition, treatment of high-risk DLBCL with R-CHOP alone showed a higher incidence of relapse than the auto-HSCT group (20 of 35 patients [57.1%] vs. 6 of 23 patients [26.1%, \( p = 0.020 \)). Among the 20 patients who relapsed after R-CHOP alone, 13 died of disease progression during salvage chemotherapy, and only one patient remains alive with CR after salvage chemotherapy. Among the remaining six patients who were treated with second-line auto-HSCT after salvage chemotherapy, two (33.3%) are alive with CR, but four patients (66.7%) relapsed.

### DISCUSSION

Prior to the advent of rituximab, the benefits of frontline auto-HSCT were verified mostly in good responders to induction chemotherapy [6]. Furthermore, several studies reported that the outcome of auto-HSCT was worse than that of chemotherapy alone when an abbreviated course of chemotherapy was performed before auto-HSCT, or when auto-HSCT was applied as an early intensified therapy. Three studies—the French randomized trial LNH93 to 3 [7], an Italian multicenter randomized trial [8], and a phase III study from the German Lymphoma Study Group [25]—that addressed early intensification with auto-HSCT showed no significant difference in OS or PFS compared to conventional che-
motherapy. These studies showed that achieving CR with full courses of induction therapy before frontline auto-HSCT is important, and that auto-HSCT should not be performed too early during the course of treatment. Although some of the results showed the possible role of frontline auto-HSCT, the role of auto-HSCT as a first line treatment is still a matter of debate in the present rituximab era.

Recently, one phase III randomized study reported high-risk DLBCL with an aaIPI score ≥ 2 with an age range of 18 to 65 years. All of the patients received eight cycles of R-CHOP with two different doses, and one arm underwent auto-HSCT followed by BEAM conditioning. The authors reported that auto-HSCT showed a 70% 3-year PFS compared to 59% in the chemotherapy alone group ($p = 0.010$), but the 3-year OS was 81% in the

![Figure 2. Kaplan-Meier estimated (A) overall survival and (B) progression-free survival in the entire cohort according to age-adjusted International Prognostic Index (aaIPI) score.](image)

![Figure 3. Kaplan-Meier estimated (A) overall survival, (B) progression-free survival, and (C) event-free survival of the entire cohort stratified based on risk and final treatment strategies. R-CHOP, rituximab plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), prednisolone; HSCT, hematopoietic stem cell transplantation; CR complete response.](image)
auto-HSCT group compared to 78% in the chemotherapy-alone group; the difference not statistically significant between the two treatment arms ($p = 0.556$) [9]. The SWOG S9704 study also showed similar results in high-risk DLBCL patients with an IPI score $\geq 3$, and showed a favorable 2-year PFS ($p = 0.005$) in auto-HSCT after six cycles of $R \pm CHOP$ compared to eight cycles of $R \pm CHOP$ alone. However, this study included patients who were not treated with rituximab [11,12]. Another phase III study analyzed the possible role of repetitive dose-escalated sequential chemotherapy followed by repetitive auto-HSCT in high-risk DLBCL patients with $aaIPI \geq 2$. However, this protocol was somewhat different from traditional ones, and the results were confounded by the toxicity of high-dose chemotherapy [26].

In contrast, we believe that our study cohort satisfied the following conditions: first, all of the patients were treated with six full cycles of $R$-CHOP; second, all of the patients achieved CR by FDG-PET criteria after six cycles of $R$-CHOP; third, all of the patients who were recommended for frontline auto-HSCT satisfied the high-risk criteria of $aaIPI \geq 2$, which included both an elevated LDH level and Ann Arbor stage III to IV. Several studies have shown that the pre-HSCT disease status evaluated by FDG-PET was the most significant independent factor for the prediction of relapse after auto-HSCT [27-29]. It is now clearly suggested that patients with persistent FDG-PET positivity do not benefit from auto-HSCT; therefore, we used interim FDG-PET every three cycles of $R$-CHOP or before auto-HSCT. All of the 58 high-risk patients in this study satisfied the pre-HSCT condition that included the regression of previously enlarged mass lesions clinically and on conventional CT examination with a complete metabolic response by FDG-PET before HSCT.

Several prognostic factors that may predict the outcome of auto-HSCT were identified in relapsed or refractory DLBCL. As described above, the benefit of auto-HSCT has been verified mostly in chemosensitive disease with negative residual disease activity before transplantation [6,28]. In addition, Hamlin et al. [18] evaluated $aaIPI$ at the initiation of second-line chemotherapy in relapsed or refractory DLBCL patients who were treated with salvage chemotherapy followed by auto-HSCT. They compared three $aaIPI$ subgroups and showed significantly different predictable values for OS and PFS, and also presented the possibility as a useful prognostic marker for evaluating new treatment approaches. In addition, some studies evaluated $aaIPI$ and pre-HSCT FDG-PET findings simultaneously. One

![Figure 4. Kaplan-Meier estimated (A) overall survival and (B) progression-free survival according to the treatment strategy in the high-risk diffuse large B-cell lymphoma group. CR complete response; HSCT, hematopoietic stem cell transplantation; R-CHOP, rituximab plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), prednisolone.](image-url)
Yoon JH, et al. Frontline autologous-HSCT for high-risk DLBCL

study showed that only FDG-PET was significantly predictive of survival outcome, and another showed that both aalIPI and FDG-PET were independent predictors of failure-free survival [30,31]. We tried to use aalIPI to determine the high-risk DLBCL patients who were scheduled to undergo frontline auto-HSCT. Our data finally showed the criteria are useful with statistical significance for the determination of high-risk DLBCL; for high-risk chemosensitive DLBCL, we may also expect better treatment outcomes with frontline auto-HSCT in the rituximab era.

Among the 58 high-risk patients who completed treatment with either auto-HSCT or R-CHOP alone, we identified 26 relapsed patients (six patients after frontline auto-HSCT and 20 patients after R-CHOP alone). Among the 20 relapsed patients after R-CHOP alone, 14 underwent salvage chemotherapy, and six received second-line auto-HSCT. Finally, only three patients (15.0%; two after auto-HSCT and one after salvage chemotherapy) are alive without disease progression at the time of analysis. These data cautiously suggest that the role of auto-HSCT for a long-term survival outcome after relapse is questionable for patients with high-risk DLBCL.

Unfortunately, we did not perform gene expression profiling to analyze the different sub-entities of DLBCL. Although DLBCL is a well-defined entity, it is heterogeneous, and many biomarkers are being investigated to understand its biological basis. Thus, even patients with the same IPI score may exhibit extreme variability in treatment outcomes, suggesting the presence of heterogeneity. Furthermore, in addition to rituximab, several novel agents have been deemed useful based on the genetic subentities in DLBCL; thus, the role of auto-HSCT might be challenged more strongly in the near future.

Although our results did not originate from a prospective clinical trial, the minimal dataset prevents definite conclusions. Furthermore, the treatments between the R-CHOP alone and frontline auto-HSCT groups were performed strictly according to the patient’s decision, a finding that could cause a selection bias in the present study. However, two high-risk groups presented well-matched comparative parameters with acceptable results, possibly supporting recent large prospective trials [9-12,26]. In conclusion, our data suggest that auto-HSCT may have a beneficial effect in chemosensitive high-risk DLBCL patients compared to R-CHOP alone.

High-risk DLBCL patients who are fit for frontline auto-HSCT may be identified by aalIPI, which satisfies the criteria of an elevated LDH level and higher Ann Arbor stages at diagnosis.

**KEY MESSAGE**

1. Frontline autologous hematopoietic stem cell transplantation can be considered for high-risk diffuse large B-cell lymphoma patients with the expectation of favorable survival outcomes.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A1208e3).

**REFERENCES**

1. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987;316:1493-1498.
2. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562-3568.
3. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 2000;18:3025-3030.
4. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796-2802.
5. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295.

6. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma: results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338-346.

7. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-2479.

8. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003;21:1255-1262.

9. Vitolo U, Chiappella A, Brusamolino E, et al. Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL). Paper presented at: 54th ASH Annual Meeting Abstracts 2012; 2012 Dec 8-11; Atlanta, GA. Washington, DC: American Society of Hematology, 2012: 688.

10. Cortelazzo S, Tarella C, Gianni AM, et al. Chemoinmunotherapy with R-CHOP or high dose sequential therapy with autologous stem cell transplantation (R-HDS) for high risk diffuse large B-cell lymphomas patients: results of the randomized R-HDS0305 trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). Paper presented at: 54th ASH Annual Meeting Abstracts 2012; 2012 Dec 8-11; Atlanta, GA. Washington, DC: American Society of Hematology, 2012: 746.

11. Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 2012;30(Suppl):abstr8001.

12. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 2013;369:1681-1690.

13. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.

14. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol 2002;29:18-22.

15. Gang AO, Strom C, Pedersen M, et al. R-CHOP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14: a population-based investigation from the Danish Lymphoma Group. Ann Oncol 2012;23:147-153.

16. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:577-578.

17. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-994.

18. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;101:1970-1996.

19. Jardin F, Jais JP, Molina TJ, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010;116:1092-1104.

20. Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol 2013;31:10-17.

21. Wolff JE, Finlay JL. High-dose chemotherapy in childhood brain tumors. Onkologie 2004;27:239-245.

22. DE Ioris MA, Contoli B, Jenkner A, et al. Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. Anticancer Res 2012;32:5527-5533.

23. Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH. Exces
sive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 2010;45:801-802.
24. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;5:306-315.
25. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 2002;20:4413-4419.
26. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250-1259.
27. Alousi AM, Saliba RM, Okorji GJ, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 2008;142:786-792.
28. Filmont JE, Giselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110:1361-1369.
29. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-419.
30. Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:2496-2503.
31. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486-491.